Press releases

Filter by year:

GeNeuro and FondaMental Foundation announce the first results of the collaboration for the development of diagnostic and therapeutic options for patients with post-COVID neuropsychiatric syndromes

Geneva, Switzerland, April 13, 2022 - 7:30 am CEST - GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), and the FondaMental Foundation, a scientific cooperation foundation serving patients with mental illness, presented at the Schizophrenia International Research Society (SIRS) congress from April 6 to 10 in Florence, Italy, the first data resulting from their collaboration launched in 2021, in the context of COVID.

GeNeuro Reports 2021 Full-Year Results and Provides Corporate Update

Geneva, Switzerland, April 4, 2022 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and severe neuropsychiatric consequences of COVID-19 (post-COVID), reports today its full-year results for the year ended December 31, 2021 and provided a corporate update.

ProTEct-MS Phase 2 trial confirms safety of higher doses of temelimab and synergistic potential to address neurodegeneration on top of anti-inflammatory treatment in multiple sclerosis

Geneva, Switzerland, March 21, 2022 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis, today announced that the top-line results of the ProTEct-MS study confirm the excellent safety profile and tolerability of higher doses of temelimab, up to 54mg/kg, used in combination with rituximab, a high-efficacy anti-CD20 drug, thus meeting the primary endpoint of the ProTEct-MS study.

GeNeuro announces the completion of its ProTEct-MS study and confirms the March timeline for top-line results, provides a Business Update and Cash Position as of December 31, 2021

Geneva, Switzerland, January 27, 2022 – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and severe neuropsychiatric consequences of COVID-19 (post-COVID), announced today that it has completed its ProTEct-MS clinical trial. The Company also reported its cash position as of December 31, 2021 and provided a business update.

Start Page      Previous Page      Results 11-14 of 14